Drug Discovery Company for Innovative Next-Generation Treatments
ONCOBIX is working toward developing innovative therapies for rare and incurable diseases with challenging treatments.
Non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases worldwide, has been on an upward trend since 2000 due to air pollution, chemical products, and genetic mutations. Notably, 10-15% of all lung cancer patients have developed resistance to conventional drugs and now suffer without standard treatment. With our own platform technology, ONCOBIX aims to overcome this resistance to currently available treatments. We have established pipelines to study and develop globally competitive fourth-generation drugs for NSCLC and pulmonary fibrosis. Our promise is to contribute to the health and well-being of humanity, delivering a better quality of life and longevity to patients suffering from diseases.
MISSION & VISION
With the innovative TOFPOMICS® platform technology, we present solutions to diseases without standard treatment, becoming a global leader in innovative drug discovery and contributing to the health and well-being of humanity.
Developing innovative new drugs
based on platform technology
to contribute to the health
and well-being of humanity
Presenting solutions to unmet needs
of rare, incurable diseases
People who share the same objectives, collaborate, and have a growth mindset
People who take on challenges with innovative thinking
People who prioritize integrity and ethics
Patents (As of May 2022)
The technical excellence of ONCOBIX is recognized by its patents pending and registered.
|Patent Pending (incl. trademark)||Registered patent in Korea||PCT patent pending||Patent pending in individual countries||Registered patent in individual countries|
|14 cases (16 registrations)||2 cases||4 cases||30 cases||5 cases (USA, Russia, Australia, Japan, Canada)|